Rhumbline Advisers Buys 2,100 Shares of SiBone (NASDAQ:SIBN)

Rhumbline Advisers lifted its stake in shares of SiBone (NASDAQ:SIBN) by 3.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 59,721 shares of the company’s stock after acquiring an additional 2,100 shares during the quarter. Rhumbline Advisers owned approximately 0.14% of SiBone worth $838,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in the stock. American Century Companies Inc. raised its position in shares of SiBone by 11.0% during the fourth quarter. American Century Companies Inc. now owns 2,378,068 shares of the company’s stock worth $33,341,000 after acquiring an additional 236,167 shares during the last quarter. Silvercrest Asset Management Group LLC increased its holdings in SiBone by 21.9% in the fourth quarter. Silvercrest Asset Management Group LLC now owns 1,953,806 shares of the company’s stock worth $27,392,000 after purchasing an additional 350,970 shares in the last quarter. Paradigm Capital Management Inc. NY increased its holdings in SiBone by 5.3% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 1,386,031 shares of the company’s stock worth $19,432,000 after purchasing an additional 69,831 shares in the last quarter. Nuveen Asset Management LLC increased its holdings in SiBone by 17.8% in the fourth quarter. Nuveen Asset Management LLC now owns 1,263,988 shares of the company’s stock worth $17,721,000 after purchasing an additional 190,830 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in SiBone by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 933,891 shares of the company’s stock worth $13,097,000 after purchasing an additional 9,847 shares in the last quarter. 98.11% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

SIBN has been the subject of a number of research analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $24.00 target price on shares of SiBone in a report on Tuesday, May 6th. Truist Financial lifted their target price on SiBone from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Tuesday, May 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $25.00 target price on shares of SiBone in a report on Tuesday, May 6th.

SiBone Trading Down 1.7%

Shares of SiBone stock opened at $16.39 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 7.26 and a current ratio of 8.53. SiBone has a 52 week low of $11.70 and a 52 week high of $20.05. The stock has a 50 day moving average price of $16.94 and a two-hundred day moving average price of $15.85. The stock has a market capitalization of $698.54 million, a PE ratio of -25.61 and a beta of 0.94.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.09. SiBone had a negative return on equity of 16.00% and a negative net margin of 15.03%. The firm had revenue of $47.29 million during the quarter, compared to analysts’ expectations of $45.13 million. As a group, equities analysts anticipate that SiBone will post -0.78 earnings per share for the current fiscal year.

Insider Buying and Selling at SiBone

In related news, CFO Anshul Maheshwari sold 2,424 shares of SiBone stock in a transaction that occurred on Monday, May 19th. The stock was sold at an average price of $19.48, for a total transaction of $47,219.52. Following the transaction, the chief financial officer now owns 222,083 shares of the company’s stock, valued at $4,326,176.84. The trade was a 1.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Laura Francis sold 12,385 shares of SiBone stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $19.67, for a total value of $243,612.95. Following the transaction, the chief executive officer now directly owns 495,170 shares in the company, valued at approximately $9,739,993.90. The trade was a 2.44% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 95,942 shares of company stock valued at $1,734,203. Company insiders own 4.00% of the company’s stock.

SiBone Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.